{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:05:25Z","timestamp":1765883125550,"version":"3.48.0"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2015"],"award-info":[{"award-number":["01KG2015"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,1,29]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Guidelines recommend clozapine for treatment-resistant schizophrenia. However, meta-analysis of aggregate data (AD) did not demonstrate higher efficacy of clozapine compared with other second-generation antipsychotics but found substantial heterogeneity between trials and variation between participants in treatment effects. Therefore, we will conduct an individual participant data (IPD) meta-analysis to estimate the efficacy of clozapine compared with other second-generation antipsychotics while accounting for potentially important effect modifiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In a systematic review, two reviewers will independently search Cochrane Schizophrenia Group\u2019s trial register (without restrictions in date, language or state of publication) and related reviews. We will include randomised controlled trials (RCTs) in participants with treatment-resistant schizophrenia comparing clozapine with other second-generation antipsychotics for at least 6 weeks. We will apply no restrictions in age, gender, origin, ethnicity or setting, but exclude open-label studies, studies from China, experimental studies and phase II of cross-over trials. IPD will be requested from trial authors and cross-check against published results. AD will be extracted in duplicate. Risk of bias will be assessed using Cochrane\u2019s Risk of Bias 2 tool.<\/jats:p>\n                    <jats:p>The primary outcome will be overall symptoms of schizophrenia.<\/jats:p>\n                    <jats:p>We will synthesise results using random-effects meta-analysis and meta-regression methods in a 3-level Bayesian model. The model combines IPD with AD when IPD is not available for all studies, and include participant, intervention and study design characteristics as potential effect modifiers. The effect size measures will be mean difference (or standardised mean difference when different scales were used). Confidence in the evidence will be assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This project has been approved by the ethics commission of the Technical University of Munich (#612\/21\u2009S-NP). The results will be published open-access in a peer-review journal and a plain-language version of the results will be disseminated.<\/jats:p>\n                    <jats:p>If we need to amend this protocol, we will describe the change and give the rationale in a specific section in the resulting publication \u2018Changes with respect to the protocol\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO (#CRD42021254986)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064504","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T10:19:13Z","timestamp":1676974753000},"page":"e064504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4700-6990","authenticated-orcid":false,"given":"Tasnim","family":"Hamza","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"},{"name":"Graduate School of Health Sciences, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5661-5149","authenticated-orcid":false,"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-0545","authenticated-orcid":false,"given":"Shimeng","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulf-Peter","family":"Hansen","sequence":"additional","affiliation":[{"name":"BASTA - B\u00fcndnis f\u00fcr psychisch erkrankte Menschen, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[{"name":"Psychiatric Institute, University of Illinois at Chicago, Chicago, Illinois, USA"},{"name":"Department of Psychiatry, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-8508","authenticated-orcid":false,"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2025121603010456000_13.2.e064504.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"2025121603010456000_13.2.e064504.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01121-6"},{"key":"2025121603010456000_13.2.e064504.3","unstructured":"National Institute for Health and Care Excellence . Psychosis and schizophrenia in adults: prevention and managment: clinical guideline [CG178]. 2014. Available: https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"2025121603010456000_13.2.e064504.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr"},{"key":"2025121603010456000_13.2.e064504.5","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"2025121603010456000_13.2.e064504.6","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 1 September 2020. doi:10.1176\/appi.books.9780890424841","DOI":"10.1176\/appi.books.9780890424841"},{"key":"2025121603010456000_13.2.e064504.7","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","volume":"2010","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121603010456000_13.2.e064504.8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2025121603010456000_13.2.e064504.9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"2025121603010456000_13.2.e064504.10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.4.518"},{"key":"2025121603010456000_13.2.e064504.11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","article-title":"Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis","volume":"45","author":"Mizuno","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2025121603010456000_13.2.e064504.12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"2025121603010456000_13.2.e064504.13","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025121603010456000_13.2.e064504.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i3507","article-title":"When and how to update systematic reviews: consensus and checklist","volume":"354","author":"Garner","year":"2016","journal-title":"BMJ"},{"key":"2025121603010456000_13.2.e064504.15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8516"},{"key":"2025121603010456000_13.2.e064504.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025121603010456000_13.2.e064504.17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2022.01.001","article-title":"About the issue of including or excluding studies from china in systematic reviews","volume":"240","author":"Leucht","year":"2022","journal-title":"Schizophr Res"},{"key":"2025121603010456000_13.2.e064504.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.140"},{"key":"2025121603010456000_13.2.e064504.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"2025121603010456000_13.2.e064504.20","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"2025121603010456000_13.2.e064504.21","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"2025121603010456000_13.2.e064504.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.008"},{"key":"2025121603010456000_13.2.e064504.23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2025121603010456000_13.2.e064504.24","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"2025121603010456000_13.2.e064504.25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"Bioimpacts"},{"key":"2025121603010456000_13.2.e064504.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Syst Rev"},{"key":"2025121603010456000_13.2.e064504.27","doi-asserted-by":"crossref","unstructured":"Shokraneh F , Adams CE . Cochrane schizophrenia group\u2019s study-based register of randomized controlled trials: development and content analysis. Schizophrenia Bulletin Open 2020;1. doi:10.1093\/schizbullopen\/sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061"},{"key":"2025121603010456000_13.2.e064504.28","doi-asserted-by":"crossref","unstructured":"Shokraneh F , Adams CE . Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis. Health Info Libr J 18, 2021. doi:10.1111\/hir.12366","DOI":"10.1111\/hir.12366"},{"key":"2025121603010456000_13.2.e064504.29","unstructured":"Lefebvre C , Glanville J , Briscoe S , et al . Chapter 4: searching for and selecting studies. In: Higgins JPT , Thomas J , Chandler J , et al ., eds. Cochrane Handbook for Systematic Reviews of Interventions: version 6.3. 2022."},{"key":"2025121603010456000_13.2.e064504.30","unstructured":"R Core . R: A language and environment for statistical computing, Vienna, Austria. 2018. Available: https:\/\/www.R-project.org\/"},{"key":"2025121603010456000_13.2.e064504.31","unstructured":"Hadley Wickham, Evan Miller. haven: import and export \u2019SPSS\u2019, \u2019stata\u2019 and \u2019SAS\u2019 files. 2021. Available: https:\/\/CRAN.R-project.org\/package=haven"},{"key":"2025121603010456000_13.2.e064504.32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"JOSS"},{"key":"2025121603010456000_13.2.e064504.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.11.004"},{"key":"2025121603010456000_13.2.e064504.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026137","article-title":"Dismantling, personalising and optimising internet cognitive-behavioural therapy for depression: a study protocol for individual participant data component network meta-analysis","volume":"8","author":"Furukawa","year":"2019","journal-title":"BMJ Open"},{"key":"2025121603010456000_13.2.e064504.35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophr Bull"},{"key":"2025121603010456000_13.2.e064504.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025121603010456000_13.2.e064504.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2916"},{"key":"2025121603010456000_13.2.e064504.38","unstructured":"Plummer M . JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. In: Proceedings of the 3rd international workshop on distributed statistical computing. 2003: 1\u201310."},{"key":"2025121603010456000_13.2.e064504.39","unstructured":"Sch\u00fcnemann H , Bro\u017cek J , Guyatt G , et al ., eds. GRADE handbook for grading quality of evidence and strength of recommendation: updated October 2013: the GRADE working group 2013. 2013."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:01:14Z","timestamp":1765882874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjopen-2022-064504"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064504","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}